Cargando…
Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute
BACKGROUND: The aim of this study was to evaluate the combined use of the overactive bladder symptom score (OABSS) and International Prostate Symptom Score (IPSS) as an assessment tool for urinary symptom flare after iodine-125 ((125)I) implant brachytherapy. The association between urinary symptom...
Autores principales: | Miyake, Makito, Tanaka, Nobumichi, Asakawa, Isao, Hori, Shunta, Morizawa, Yosuke, Tatsumi, Yoshihiro, Nakai, Yasushi, Inoue, Takeshi, Anai, Satoshi, Torimoto, Kazumasa, Aoki, Katsuya, Hasegawa, Masatoshi, Fujii, Tomomi, Konishi, Noboru, Fujimoto, Kiyohide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5556596/ https://www.ncbi.nlm.nih.gov/pubmed/28806948 http://dx.doi.org/10.1186/s12894-017-0251-1 |
Ejemplares similares
-
Oncological outcome, complications, lower urinary tract symptoms, and health-related quality of life after low-dose-rate salvage brachytherapy for recurrent prostate cancer following primary radiotherapy: a report of 8 cases
por: Miyake, Makito, et al.
Publicado: (2017) -
Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer
por: Onishi, Kenta, et al.
Publicado: (2018) -
Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia
por: Gotoh, Daisuke, et al.
Publicado: (2022) -
Quality of life in patients who underwent (125)I brachytherapy, (125)I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer
por: Nakai, Yasushi, et al.
Publicado: (2019) -
Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil -
por: Tanaka, Nobumichi, et al.
Publicado: (2014)